<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(12)</volume><submitter>Singier A</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Although pharmacovigilance signals and a strong pathophysiological rationale have suggested a potential risk of arterial dissections or aneurysms associated with angiogenesis inhibitors, this association deserves to be further investigated through clinical practice evidence studies.&lt;h4>Objective&lt;/h4>To evaluate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms in patients treated for metastatic colorectal cancer (mCRC).&lt;h4>Design, setting, and participants&lt;/h4>A nested case-control study was conducted within a cohort of adults initiating targeted therapy (angiogenesis or epidermal growth factor receptor inhibitors) for mCRC between January 1, 2012, and December 31, 2017. Data were analyzed from April 2021 </pubmed_abstract><journal>JAMA network open</journal><pagination>e2546960</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12679322</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer.</pubmed_title><pmcid>PMC12679322</pmcid><pubmed_authors>Jarne Munoz A</pubmed_authors><pubmed_authors>Pariente A</pubmed_authors><pubmed_authors>Noize P</pubmed_authors><pubmed_authors>Maumus-Robert S</pubmed_authors><pubmed_authors>Singier A</pubmed_authors><pubmed_authors>Berard X</pubmed_authors><pubmed_authors>Bezin J</pubmed_authors><pubmed_authors>Kempf E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer.</name><description>&lt;h4>Importance&lt;/h4>Although pharmacovigilance signals and a strong pathophysiological rationale have suggested a potential risk of arterial dissections or aneurysms associated with angiogenesis inhibitors, this association deserves to be further investigated through clinical practice evidence studies.&lt;h4>Objective&lt;/h4>To evaluate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms in patients treated for metastatic colorectal cancer (mCRC).&lt;h4>Design, setting, and participants&lt;/h4>A nested case-control study was conducted within a cohort of adults initiating targeted therapy (angiogenesis or epidermal growth factor receptor inhibitors) for mCRC between January 1, 2012, and December 31, 2017. Data were analyzed from April 2021 </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-05T22:34:40.873Z</modification><creation>2026-05-23T03:08:48.616Z</creation></dates><accession>S-EPMC12679322</accession><cross_references><pubmed>41343210</pubmed><doi>10.1001/jamanetworkopen.2025.46960</doi></cross_references></HashMap>